Vanta has announced its $150 million Series D funding round at a $4.15 billion valuation. The round was led by new investor Wellington Management, and included existing investors, Growth Equity at Goldman Sachs Alternatives, Sequoia, J.P. Morgan, Craft Ventures, Y Combinator, Atlassian Ventures and CrowdStrike Ventures. The funding brings Vanta’s total funds raised to $504 million since 2021.
AI continues to dominate headlines and social media. For good reason. It’s already helping many businesses work faster and smarter. The global AI market was worth more than $279 billion last year. It’s expected to grow to $1.8 trillion by 2030. That kind of growth tells you how quickly things are moving.
Slumps in business performance are increasingly destabilising work-life balances. In 2024 sales declined, with just over half (57%) of salespeople reaching their sales targets. This is the lowest figure in five years, marking a continuing trend of attrition: 4% lower than the previous year and 7% lower than in 2021.
From predictive maintenance at Rolls-Royce to hyper-personalised retail at John Lewis, AI is no longer a future goal, it’s the engine of smarter operations, sharper decision-making, and competitive edge, with startups that are embedding AI early and meaningfully into their products and processes already pulling ahead.
The global medtech and healthtech startup community has no shortage of bold ideas. Across the world, early-stage companies are developing digital tools, medical devices, and AI-driven solutions aimed at tackling some of the most complex challenges in healthcare. Yet, while innovation flourishes, scaling successfully remains notoriously difficult.














